Bright Minds Biosciences (DRUG) Competitors $28.30 +0.29 (+1.04%) Closing price 07/3/2025 03:27 PM EasternExtended Trading$27.00 -1.30 (-4.59%) As of 07/3/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. GHRS, STOK, SANA, MRVI, URGN, AUTL, CDXC, CDTX, ABUS, and EOLSShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include GH Research (GHRS), Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), Urogen Pharma (URGN), Autolus Therapeutics (AUTL), ChromaDex (CDXC), Cidara Therapeutics (CDTX), Arbutus Biopharma (ABUS), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Its Competitors GH Research Stoke Therapeutics Sana Biotechnology Maravai LifeSciences Urogen Pharma Autolus Therapeutics ChromaDex Cidara Therapeutics Arbutus Biopharma Evolus GH Research (NASDAQ:GHRS) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings. Does the media prefer GHRS or DRUG? In the previous week, Bright Minds Biosciences had 3 more articles in the media than GH Research. MarketBeat recorded 8 mentions for Bright Minds Biosciences and 5 mentions for GH Research. GH Research's average media sentiment score of 0.34 beat Bright Minds Biosciences' score of 0.04 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Minds Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, GHRS or DRUG? GH Research has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -6.01, meaning that its share price is 701% less volatile than the S&P 500. Which has stronger valuation and earnings, GHRS or DRUG? Bright Minds Biosciences is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$38.96M-$0.79-18.87Bright Minds BiosciencesN/AN/A-$2.06M-$0.36-78.61 Is GHRS or DRUG more profitable? Bright Minds Biosciences' return on equity of -14.56% beat GH Research's return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -19.20% -18.40% Bright Minds Biosciences N/A -14.56%-14.29% Do analysts rate GHRS or DRUG? GH Research currently has a consensus price target of $32.00, suggesting a potential upside of 114.62%. Bright Minds Biosciences has a consensus price target of $83.25, suggesting a potential upside of 194.17%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Do insiders and institutionals have more ownership in GHRS or DRUG? 56.9% of GH Research shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryBright Minds Biosciences beats GH Research on 9 of the 13 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$199.84M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E Ratio-78.6121.5627.6520.23Price / SalesN/A283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book30.767.538.035.65Net Income-$2.06M-$55.14M$3.18B$249.15M7 Day Performance21.62%4.61%2.93%3.28%1 Month Performance2.50%0.90%1.72%3.95%1 Year Performance2,594.98%5.40%34.39%20.98% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences2.8403 of 5 stars$28.30+1.0%$83.25+194.2%+2,595.0%$199.84MN/A-78.61N/ANews CoverageAnalyst ForecastAnalyst RevisionGHRSGH Research1.5715 of 5 stars$12.19-2.0%$32.00+162.5%+26.9%$647.23MN/A-15.4310News CoverageAnalyst UpgradeSTOKStoke Therapeutics4.0255 of 5 stars$11.35-2.4%$23.20+104.4%-12.5%$634.96M$190.91M14.37100News CoverageAnalyst ForecastSANASana Biotechnology2.7581 of 5 stars$2.73-2.8%$8.60+215.0%-37.2%$633.59MN/A-3.10380Analyst ForecastGap UpMRVIMaravai LifeSciences3.7463 of 5 stars$2.41-2.4%$6.64+175.5%-60.4%$629.01M$259.18M-2.11610URGNUrogen Pharma4.4708 of 5 stars$13.70+1.6%$32.86+139.8%-15.1%$621.99M$90.40M-4.31200AUTLAutolus Therapeutics2.5424 of 5 stars$2.28-1.3%$9.32+308.8%-31.3%$614.79M$10.12M-2.59330CDXCChromaDex3.1989 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120CDTXCidara Therapeutics4.2339 of 5 stars$48.71-1.5%$57.14+17.3%+296.6%$603.74M$1.27M-1.6590High Trading VolumeABUSArbutus Biopharma1.4507 of 5 stars$3.09-1.3%$5.50+78.0%+3.7%$599.48M$6.17M-7.5490EOLSEvolus3.6908 of 5 stars$9.21+0.8%$23.75+157.9%-15.2%$589.31M$266.27M-10.35170Positive News Related Companies and Tools Related Companies GH Research Competitors Stoke Therapeutics Competitors Sana Biotechnology Competitors Maravai LifeSciences Competitors Urogen Pharma Competitors Autolus Therapeutics Competitors ChromaDex Competitors Cidara Therapeutics Competitors Arbutus Biopharma Competitors Evolus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
